Response to AML induction treatment after previous treatment of MDS with a demethylating agent
| Patient no. . | Sex/ age . | MDS1-1-150 . | Response to DAC (total no. courses) . | Induction, consolidation for AML . | Response to induction . |
|---|---|---|---|---|---|
| 1003 | M/66 | RAEB-T | PD (1) | Dauno/AraC, Amsa/AraC | CR (7) |
| 1008 | M/59 | RA | CR (7) | Ida/AraC/Etoposide | PR (died during consolidation) |
| 1009 | M/71 | RAEB-1 | SD (9) | Dauno/AraC | Septic death |
| 2013 | M/60 | RAEB-2 | PD (1) | Dauno/AraC/ Etoposide, BuCy + PBSCT | CR (7) |
| 4008 | M/62 | RAEB-T | PD (1) | Amsa/AraC | PR (6) |
| 4010 | F/54 | RA | PD (1) | Ida/AraC | NR |
| 4015 | F/50 | RAEB-1 | PR (7) | Ida/AraC | NR |
| 4019 | F/62 | RAEB-2 | Impr (7) | S-HAM, S-HAM, BCNU/Mel + PBSCT | CR (8) |
| 4021 | M/61 | RAEB-T | PD (1) | Ida/AraC | NR |
| 8001 | M/71 | RAEB-1 | PR (3) | Dauno/AraC | PR (4) |
| 8006 | M/61 | RAEB-T | PD (2) | Dauno/AraC | CR (5) |
| 8010 | M/64 | RAEB-2 | CR (6) | Dauno/AraC, Mito/Etoposide | CR (3) |
| 8012 | M/63 | RAEB-T | PD (1) | Dauno/AraC | Multi-organ failure |
| 8021 | M/77 | RAEB-2 | CR (6) | Dauno/AraC | PR |
| 8026 | M/66 | RAEB-T | CR (6) | Dauno/AraC | CR (7+) |
| Patient no. . | Sex/ age . | MDS1-1-150 . | Response to DAC (total no. courses) . | Induction, consolidation for AML . | Response to induction . |
|---|---|---|---|---|---|
| 1003 | M/66 | RAEB-T | PD (1) | Dauno/AraC, Amsa/AraC | CR (7) |
| 1008 | M/59 | RA | CR (7) | Ida/AraC/Etoposide | PR (died during consolidation) |
| 1009 | M/71 | RAEB-1 | SD (9) | Dauno/AraC | Septic death |
| 2013 | M/60 | RAEB-2 | PD (1) | Dauno/AraC/ Etoposide, BuCy + PBSCT | CR (7) |
| 4008 | M/62 | RAEB-T | PD (1) | Amsa/AraC | PR (6) |
| 4010 | F/54 | RA | PD (1) | Ida/AraC | NR |
| 4015 | F/50 | RAEB-1 | PR (7) | Ida/AraC | NR |
| 4019 | F/62 | RAEB-2 | Impr (7) | S-HAM, S-HAM, BCNU/Mel + PBSCT | CR (8) |
| 4021 | M/61 | RAEB-T | PD (1) | Ida/AraC | NR |
| 8001 | M/71 | RAEB-1 | PR (3) | Dauno/AraC | PR (4) |
| 8006 | M/61 | RAEB-T | PD (2) | Dauno/AraC | CR (5) |
| 8010 | M/64 | RAEB-2 | CR (6) | Dauno/AraC, Mito/Etoposide | CR (3) |
| 8012 | M/63 | RAEB-T | PD (1) | Dauno/AraC | Multi-organ failure |
| 8021 | M/77 | RAEB-2 | CR (6) | Dauno/AraC | PR |
| 8026 | M/66 | RAEB-T | CR (6) | Dauno/AraC | CR (7+) |
Criteria for response of MDS to 5-aza-2′-deoxycytidine (decitabine; DAC) treatment were as described,1-1for response of AML to induction treatment were as previously applied by the EORTC-LCG.1-12
CR indicates complete remission; PR, partial remission; Impr, hematologic improvement; SD, stable disease; NR, no response, PD, progressive disease; Amsa, amsacrine; AraC, cytarabine; BuCy, busulfan/cyclophosphamide; Dauno, daunorubicin; Ida, idarubicin; Mel, melphalan; Mito, mitoxantrone; PBSCT, autologous peripheral blood stem cell transplantation; and S-HAM, sequential high-dose AraC/mitoxantrone.
French-American-British (FAB) classifications.